Kronos Bio, Inc. - KRON STOCK NEWS

Kronos Bio presented promising preclinical data on its SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association (EHA) 2022 Congress. These findings bolster support for targeting spleen tyrosine kinase (SYK) in genetically defined acute myeloid leukemia (AML) subsets. The Phase 3 AGILITY trial of entospletinib is exploring its efficacy alongside chemotherapy in NPM1-mutated AML, with data expected in late 2023. The research indicates potential anti-tumor activity and improved T-cell responses, highlighting a novel therapeutic mechanism.

Kronos Bio, Inc. (Nasdaq: KRON) will have President and CEO Norbert Bischofberger participate in investor conferences. Bischofberger will appear at the Jefferies Healthcare Conference on June 8, 2022, at 4:30 p.m. ET, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 3:20 p.m. PT. Live webcasts will be accessible on the Kronos Bio website, with replays available for 30 days post-event. Kronos Bio focuses on therapies for cancer treatment, notably developing entospletinib for NPM1-mutated AML and KB-0742 for MYC-amplified tumors.

Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the H.C. Wainwright Global Investment Conference, with a webcast presentation scheduled for May 24, 2022, at 7 a.m. ET. This on-demand presentation will be accessible through their website, allowing investors to catch up after the event as a replay will be available for 30 days.

The company focuses on developing therapies for cancer, particularly through their investigational treatment, entospletinib, targeting NPM1-mutated acute myeloid leukemia.

Kronos Bio, Inc. (Nasdaq: KRON) announced the presentation of preclinical data on its investigational SYK inhibitors, entospletinib and lanraplenib, at the European Hematology Association 2022 Congress. The Phase 3 AGILITY study of entospletinib in NPM1-mutated acute myeloid leukemia (AML) is underway, with results expected in late 2023. Lanraplenib is being tested in a Phase 1b/2 study for relapsed/refractory AML. Key findings indicate strong predictive markers for entospletinib's efficacy and synergistic effects with other targeted therapies. The company aims to advance its pipeline amid challenging market conditions.

Kronos Bio, Inc. (Nasdaq: KRON) announced its first quarter 2022 financial results and business updates, reporting a net loss of $36.3 million or $0.65 per share. The company has $315.4 million in cash and investments, ensuring a financial runway into the second half of 2024. Progress was made on three clinical programs, including the CDK9 inhibitor KB-0742, with preclinical data presented at AACR supporting its efficacy in various cancers. The company also opened additional sites for the SYK inhibitor clinical trial and plans to announce further data in Q4 2022.

Kronos Bio has showcased preclinical data on KB-0742, a selective CDK9 inhibitor, at the AACR Annual Meeting 2022. The data suggest its potential efficacy against triple-negative breast, ovarian, and small-cell lung cancers, as well as lymphoma and other rare tumors. The company is advancing its Phase 1/2 clinical trial, which began enrolling patients in February 2021, with additional results expected in Q4 2022. A new liquid biopsy assay is also being presented to evaluate patient responses. These findings support future development stages for KB-0742.

Kronos Bio (Nasdaq: KRON) is set to present preclinical data on its CDK9 inhibitor, KB-0742, at the AACR Annual Meeting 2022. This includes findings from studies on MYC-amplified cancers such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. The ongoing Phase 1/2 trial has yielded preliminary positive data, with the company expected to announce the recommended Phase 2 dose by Q4 2022. Additionally, the research features a liquid biopsy assay to monitor patient responses. The poster presentations will take place on April 12 and April 10, 2022, in New Orleans.

Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer therapies, will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. CEO Norbert Bischofberger, Ph.D., is scheduled to join the "Novel Oncology Targets" panel on March 7 at 12:50 p.m. ET. A live webcast of the discussion will be available on the company's website, with a replay archived for 30 days. Kronos is developing treatments targeting dysregulated transcription in cancer, including its lead compound, entospletinib, for NPM1-mutated acute myeloid leukemia.

Kronos Bio reported progress in its clinical pipeline and financial results for Q4 and full-year 2021. The company continues to enroll patients in the Phase 1/2 trial of the CDK9 inhibitor KB-0742, expecting to announce a recommended Phase 2 dose and updated data in Q4 2022. The Phase 3 AGILITY trial of entospletinib is underway, aiming for results in H2 2023. As of December 31, 2021, Kronos had $339.5 million in cash, expected to fund operations into H2 2024. The company's Q4 net loss was $62.3 million, or $1.13 per share.